Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-137

Hey at least there's interest in the stock either way - prop or no prop.

You are getting a little too excited with your put downs - in no way is this great news - but its certainly not cementing that Eugeni is unmarketable, its CE Approed in Europe and will be free to sell there from June 2023 when the Commons List mandate is removed and the single test is no longer the only requirement. This is the pivot.

I dont know why you think everyone is saying this is amazing - certainly not expected news, but at least theres some action from the new CEO to get things back on track.